Like the widespread selling going on now? I can't believe this action. I guess Crede is another institutional investor set to crush the little retail investors - makes me sick.
There is no question there is a market for lymphoseek. The question is how quickly market penetration can occur. It is the best products for identifying cancerous nodes EVER. Unless we have found a cure for cancer, I think there is a market for this drug.
In Oct, NAVB met phase 3 end points for use of lymphoseek in head and neck cancers, working with FDA on sNDA which should be approved in 2014.
wow, this price action is BS!!! I hope Mr. Peizer is now now also screwing around - his reputation is to help share price, now pummel it. What the f!!!
Equities, good to see you here, rational and truly appreciate your efforts. I was in medicine. Immense value to patients with lymphoseek, no doubt. Very excited about the clarity of 4794 as early diagnosis of Alzheimer's and the 10s of millions it effects can be enormous. Rigs is huge, as is the manocept platform. At this point, my investment interest is first getting even (around $3), then seeing how navb is positioned at that point. Would be thrilled with a buyout at $5.
wow, you really are paid per letter, aren't you -- accurate nodal involvement is CRITICAL to proper disease STAGING and subsequent treatment, which DOES affect survival ---- go home with your moronic lies.
wow, you really are paid per letter, aren't you -- accurate nodal involvement is CRITICAL to proper disease STAGING and subsequent treatment, which DOES affect survival ---- you are clearly not a health care provider, but paid by letter worker.
Are you confident with management and sales projections? Do you have contacts in hospitals to see if lymphoseek is actually being adopted? This is what we need to know --
Looks like cash burn around $20M/ year. They have one year to get this show on the road BIG time - with serious earnings - over $30m or I am truly concerned for their survival - too much dilution for anymore offerings. Cardinal better get this thing SOLD, and European partner needs to happen.
So you seem confident in the company's ability to outrun their $20m/yr cash burn. Do you really think sales will be there?
Thanks for your comments - my broker spoke with Larson - unless sales are strong over the next year, he is very concerned about cash burn. Your confidence is encouraging, but a bit abstract. I hope you are right.